Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12446380 | 0.82 | ALDH1A1 (0.40) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL8334782 | 0.82 | NQO2 (0.46) | ALDH1A1HSD17B10NPC1RAB9ATSHR | |
| SCHEMBL8405592 | 0.82 | ADRA2A (0.46) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL23870266 | 0.78 | ADRA2A (0.44) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL7473749 | 0.78 | ADRA2A (0.44) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL12116986 | 0.78 | ALDH1A1 (0.38) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL25166705 | 0.78 | HTT (0.38) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL14188444 | 0.78 | ALDH1A1 (0.41) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL20729436 | 0.78 | ALDH1A1 (0.39) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL16066059 | 0.78 | ADRA2A (0.44) | ADRA2AADRA2CADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9624234-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624234-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9573903-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| WO-2016002968-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150218180-A1 | Heterocyclic compounds and methods for their use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150218180-A1 | Heterocyclic compounds and methods for their use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
| WO-2013110135-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-08-01 | — | — | WO | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | ADRA2A 679/4885ADRA2C 424/4885ADRA1D 870/4885 |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3A, HTR3B | ADRA2A 41/4885ADRA2C 25/4885ADRA1D 63/4885 |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | ADRA2A 2520/4885ADRA2C 2696/4885ADRA1D 2428/4885 |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | RORC, RORB, RORA | ADRA2A 497/4885ADRA2C 475/4885ADRA1D 753/4885 |
| US-20150218180-A1 | Heterocyclic compounds and methods for their use | AGTR2, AGTR1, OPRL1 | ADRA2A 145/4885ADRA2C 99/4885ADRA1D 209/4885 |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | ADRA2A 2520/4885ADRA2C 2696/4885ADRA1D 2428/4885 |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | ADRA2A 679/4885ADRA2C 412/4885ADRA1D 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.